Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
Asian J Androl. 2012 May;14(3):393-9. doi: 10.1038/aja.2011.145. Epub 2012 Apr 16.
Prostate cancer is a clinically and molecularly heterogeneous disease. Understanding the biologic underpinning of prostate cancer is necessary to best determine how biology is associated with the risk of disease progression and how this understanding might provide insight into the development of novel therapeutic approaches. The focus of this review is on the recently identified common ETS and non-ETS gene rearrangements in prostate cancer. Although multiple molecular alterations have been detected in prostate cancer, a basic understanding of gene fusion prostate cancer should help explain the clinical and biologic diversity, providing a rationale for a molecular subclassification of the disease.
前列腺癌是一种临床表现和分子特征均存在异质性的疾病。为了更好地确定生物学特性与疾病进展风险之间的关系，以及这种关联能否为新型治疗方法的开发提供思路，我们有必要深入了解前列腺癌的生物学基础。本文重点介绍了前列腺癌中最近发现的常见 ETS 和非 ETS 基因重排。尽管在前列腺癌中已经检测到多种分子改变，但对基因融合型前列腺癌有了基本的认识，应该有助于解释其临床表现和生物学多样性，并为该疾病的分子分类提供依据。
